Pan-cancer analysis identified OAS1 as a potential prognostic biomarker for multiple tumor types

Shan Jiang; Xinzhou Deng; Ming Luo; Le Zhou; Jingjing Chai; Chao Tian; Yutao Yan; Zhiguo Luo

doi:10.3389/fonc.2023.1207081

Pan-cancer analysis identified OAS1 as a potential prognostic biomarker for multiple tumor types

Front Oncol. 2023 Sep 6:13:1207081. doi: 10.3389/fonc.2023.1207081. eCollection 2023.

Authors

Shan Jiang¹, Xinzhou Deng^{1

2}, Ming Luo¹, Le Zhou¹, Jingjing Chai¹, Chao Tian¹, Yutao Yan¹, Zhiguo Luo¹

Affiliations

¹ Department of Clinical Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
² Hubei Key Laboratory of Stem Cell Research, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.

Abstract

Background: 2',5'-oligoadenylate synthetase 1 (OAS1), has been reported as a tumor driver gene in breast carcinoma and pancreatic carcinoma. However, the role of OAS1 in most tumors has not been reported.

Methods: The original data of 35 tumor types were down load from the TCGA (The Cancer Genome Atlas) database and Human Protein Atlas (HPA) database. TIMER2, Kmplot, UALCAN, and TISIDB tools were used to investigate the expression and function of OAS1, and the role of OAS1 in prognosis, diagnostic value, and immune characteristics of pan-cancer. LUAD and PRAD cell lines, A549, H1975, PC-3 and C4-2 were utilized to perform cell function tests.

Results: OAS1 expression was up-regulated in 12 tumor types and down-regulated in 2 tumor types. High OAS1 expression was correlated with poor prognosis in 6 tumor types, while high OAS1 expression was correlated with good prognosis in 2 tumor types. OAS1 was correlated with molecular subtypes in 8 tumor types and immune subtypes in 12 tumor types. OAS1 was positively associated with the expression of numerous immune checkpoint genes and tumor mutational burden (TMB). OAS1 had potential diagnostic value in 15 tumor types. Silence of OAS1 significantly inhibited the cell proliferation ability, and promoted G2/M cell cycle arrest of LUAD and PRAD cells. Meanwhile, silence of OAS1 enhanced cisplatin-induced apoptosis of LUAD and PRAD cells, but weakened cell migration.

Conclusion: This pan-cancer study suggests that OAS1can be used as a molecular biomarker for prognosis in pan-cancer and may play an important role in tumor immune response.

Keywords: OAS1; biomarker; pan-cancer; prognosis; tumor immune response.

Grants and funding

The authors declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the National Nature Science Foundation of China (Nos. 81802997). Special Project of Central Government for Local Science and Technology Development of Hubei Province (Nos. 2022BGE270); the Natural Science Foundation of Hubei Province of China (Nos. 2022CFB082); the Natural Science Foundation of Hubei Provincial Department of Education (Nos. Q20202106, D20212101), Hubei Provincial Health Commission (Nos.WJ2021M048), the Scientific and Technological Project of Shiyan City of Hubei Province (Nos. 21Y18). Advantages Discipline Group (Medicine) Project in Higher Education of Hubei Province (Nos. 2022XKQT2). Immunoradiotherapy research fund project of Chinese Medical Association Radiation Oncology Branch (Nos. Z-2017-24-2108).